18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma

Annals of Nuclear Medicine

Volumn 26, Issue 6, 2012, Pages 478-484

  Yamane, Tomohiko ^a   Takaoka, Aki ^b   Kita, Masato ^b   Imai, Yukihiro ^b   Senda, Michio ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

18F FDG PET; 18F FLT PET; Uterine corpus tumor; Uterine leiomyoma; Uterine leiomyosarcoma

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ETHICS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; LABELING INDEX; LEIOMYOMA; LINEAR REGRESSION ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; SENSITIVITY AND SPECIFICITY; UTERUS CANCER; UTERUS MYOMA; UTERUS SARCOMA; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; BIOLOGICAL TRANSPORT; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEIOMYOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; UTERINE NEOPLASMS;

EID: 84864653206     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0597-0     Document Type: Article

References (23)

1. Sahdev A, Sohaib SA, Jacobs I, Shepherd JH, Oram DH, Reznek RH. MR imaging of uterine sarcomas. AJR Am J Roentgenol. 2001;177:1307-11. (Pubitemid 33081470)
2. 18F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging. 2010;37:1087-94.
3. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011;259:117-126.
4. Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144-51. (Pubitemid 351344556)
5. 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI. Ann Nucl Med. 2008;22:505-12.
6. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs (Who/IARC Classification of Tumours). Lyon: IARC Press; 2003.
7. Gokaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59:36-40. (Pubitemid 40082295)
8. O'Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007;50:851-8. (Pubitemid 46850073)
9. 18F-FDG. J Nucl Med. 2003;44:1426-31. (Pubitemid 39663355)
10. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-61. (Pubitemid 44877006)
11. 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35:2009-17.
12. Bradley LD. Uterine fibroid embolization: a viable alternative to hysterectomy. Am J Obstet Gynecol. 2009;201:127-35.
13. Stovall DW. Alternatives to hysterectomy: focus on global endometrial ablation, uterine fibroid embolization, and magnetic resonance-guided focused ultrasound. Menopause. 2011;18: 437-44.
14. Goldberg J, Burd I, Price FV, Worthington-Kirsch R. Leiomyosarcoma in a premenopausal patient after uterine artery embolization. Am J Obstet Gynecol. 2004;191:1733-5. (Pubitemid 39491210)
15. Iihara K, Hirano K, Fujioka Y, Sakamoto A. Leiomyosarcoma with dedifferentiation in a premenopausal patient discovered after uterine artery embolization. Pathol Int. 2007;57:681-7. (Pubitemid 47353044)
16. Nishizawa S, Inubushi M, Kido A, Miyagawa M, Inoue T, Shinohara K, et al. Incidence and characteristics of uterine leiomyomas with FDG uptake. Ann Nucl Med. 2008;22:803-10.
17. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-50S.
18. 18F- fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging. 2008;35:484-92. (Pubitemid 351661666)
19. 18F fluorodeoxyglucose PET - initial experience. Radiology. 2008;248:599-605.
20. 18F]fluorodeoxyglucose PET. Eur J Nucl Med Mol Imaging. 2011;38:1824-31.
21. Akhan SE, Yavuz E, Tecer A, Iyibozkurt CA, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99:36-42. (Pubitemid 41354580)
22. D'Angelo E, Espinosa I, Ali R, Gilks CB, Rijn M, Lee CH, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 2011;121:328-33.
23. Sreenan JJ, Prayson RA, Biscotti CV, Thornton MH, Easley KA, Hart WR. Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls. Am J Surg Pathol. 1996;20:427-32. (Pubitemid 26113348)